Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
55 SEK | +0.64% | 0.00% | -9.78% |
Apr. 25 | Swedencare AB Approves Dividend for the Year 2023, Payable on May 3, 2024 | CI |
Apr. 25 | Transcript : Swedencare AB, Q1 2024 Earnings Call, Apr 25, 2024 |
Summary
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With an expected P/E ratio at 38.56 and 24.37 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 3.62 times its current sales, is high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.78% | 796M | D+ | ||
-19.73% | 72.39B | B+ | ||
-11.01% | 6.54B | B- | ||
+15.88% | 3.43B | B- | ||
-2.92% | 3.12B | B- | ||
-0.68% | 1.4B | - | ||
-17.27% | 1.34B | B | ||
-2.73% | 1.26B | - | ||
-14.67% | 1.12B | - | ||
-5.37% | 990M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SECARE Stock
- Ratings Swedencare AB